Ticker Hub
COGT — AI Analysis & Sentiment
3 recent AI-generated analyses for COGT. Sentiment and confidence insights updated continuously.
Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
The detailed positive Phase 3 clinical data for bezuclastinib significantly strengthens its market potential in GIST. With an FDA PDUFA date in Nov...
May 30, 2026Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) with Priority Review for Bezuclastinib in Combination with Sunitinib for Patients with GIST
FDA's acceptance of the New Drug Application with Priority Review for bezuclastinib for GIST patients, coupled with a PDUFA date and no immediate c...
May 28, 2026Cogent Biosciences Announces Oral Presentation of Positive Phase 3 PEAK Trial in Gastrointestinal Stromal Tumors (GIST) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
Cogent Biosciences' announcement of positive Phase 3 data for bezuclastinib in GIST, with an upcoming ASCO presentation, provides a significant bul...
Apr 21, 2026